Compared with patients who did not have nonalcoholic hepatic steatosis, more patients with nonalcoholic hepatic steatosis were male, used dipeptidyl peptidase-4 inhibitors and had: a higher prevalence of hypertension and diabetes mellitus; higher levels of triglyceride and LDL-cholesterol; lower level of HDL-cholesterol; higher level of hemoglobin A1c; higher level of high-sensitivity CRP; (Table 1). Here, DPP4 is linked to hypertensive disorder.